Company news

Capricor Therapeutics, Inc. news in 2024

Capricor Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Capricor Therapeutics to Present at Upcoming Investor Conferences

December 1, 2024

Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency

November 19, 2024

Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 12, 2024

Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting

November 11, 2024

Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13

November 4, 2024

Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

October 17, 2024

Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock

October 16, 2024

Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress

October 10, 2024

Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

October 8, 2024

Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress

October 3, 2024

Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

September 23, 2024

Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024

September 22, 2024

Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

September 16, 2024

Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences

September 5, 2024

Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 6, 2024

Capricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7

July 30, 2024

Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

June 30, 2024

Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy

June 27, 2024

CORRECTION: Capricor Therapeutics

June 24, 2024

Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy

June 24, 2024

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway

June 10, 2024

Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

June 3, 2024

Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 12, 2024

Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

May 8, 2024

Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences

May 7, 2024

Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13

May 5, 2024

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy

April 23, 2024

Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

March 5, 2024

Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

February 28, 2024

Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy

February 26, 2024

Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29

February 21, 2024

Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization

February 19, 2024

Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2

January 23, 2024

Calls in 2024

Decks in 2024